It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent
Ju-Youn Kim(IQVIA (United Kingdom)), Ki‐Bae Seung, Kiyuk Chang(St. Mary's Hospital), Wook-Sung Chung, Hee-Yeol Kim(The Catholic University of Korea Bucheon St. Mary's Hospital), Yunseok Choi(University of Ulsan), Chul‐Soo Park(Catholic University of Korea), Man‐Young Lee(Rural Development Administration), Ami Kwon(IQVIA (United Kingdom)), Woo‐Baek Chung(IQVIA (United Kingdom))
Cited by 5
Related Papers
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound
|Journal of the American College of Cardiology|2002|1k
Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease
|New England Journal of Medicine|2008|493
Clinical Impact of Intravascular Ultrasound–Guided Chronic Total Occlusion Intervention With Zotarolimus-Eluting Versus Biolimus-Eluting Stent Implantation
|Circulation Cardiovascular Interventions|2015|304